9.85
-0.07(-0.71%)
Currency In USD
Previous Close | 9.92 |
Open | 9.86 |
Day High | 9.95 |
Day Low | 9.73 |
52-Week High | 18.75 |
52-Week Low | 8.06 |
Volume | 18,236 |
Average Volume | 76,292 |
Market Cap | 131.68M |
PE | -7.58 |
EPS | -1.3 |
Moving Average 50 Days | 9.81 |
Moving Average 200 Days | 12.37 |
Change | -0.07 |
If you invested $1000 in Greenwich LifeSciences, Inc. (GLSI) since IPO date, it would be worth $1,970 as of June 01, 2025 at a share price of $9.85. Whereas If you bought $1000 worth of Greenwich LifeSciences, Inc. (GLSI) shares 3 years ago, it would be worth $1,349.32 as of June 01, 2025 at a share price of $9.85.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial
GlobeNewswire Inc.
Apr 02, 2025 10:00 AM GMT
STAFFORD, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immun
Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026
GlobeNewswire Inc.
Mar 27, 2025 10:00 AM GMT
STAFFORD, Texas, March 27, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immun
Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01
GlobeNewswire Inc.
Mar 17, 2025 10:45 AM GMT
STAFFORD, Texas, March 17, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immun